CellGuard-TD improves human tissue digestion and cell subculturing

描述(申请人提供)：组织消化和细胞提取是各种生物处理方法的核心要素，从用于基础研究的罕见癌症干细胞的分离到用于移植的人类胰岛或脂肪来源的间充质干细胞的纯化。尽管步骤不同，但很明显，每个组织消化过程都会使完整的组织受到细胞压力，这可能会导致细胞活力和功能的丧失。CPSI-Bioech专注于改进各种人类细胞类型在常温(20至370摄氏度)下的生物处理，从而提高它们的药理和细胞治疗效用。为此，该公司正在开发CellGuard补充剂系列试剂，当添加到选定的生物处理过程中时，将保护和维持细胞的活性和功能。反过来，这将减少患者移植后或输血后的问题。这 第一阶段项目计划开发CellGuard-TD-一种旨在增强用于胰岛分离的人胰腺组织的组织消化(TD)的补充(CTDislet)。第一阶段将使用各种分子生物学方法开发CTDislet原型-第一个旨在通过细胞应激途径调节改善胰岛消化的补充剂。CTDislet将基于众所周知的人胰岛容易凋亡的性质，热缺血暴露导致的细胞产量低，以及胶原酶诱导的胰岛损伤，导致每个胰腺获得的细胞数量较少。第二阶段的研究将致力于对CTDislet进行更深入的分析和开发，并在选定的胰岛采购中心测试这一新配方。第二阶段研究的第二个目标将是开发一种“非合成的”CTDislet配方，该配方由来自植物来源的细胞应激抑制剂组成。该项目的目的是开发一种补充剂，在分离和处理过程中保护人类胰岛的脆弱性质-这项技术将适用于本地胰岛以及从间充质干细胞和其他干细胞来源分化出来的胰岛。这项研究对人类健康的影响将是改善用于治疗糖尿病的人类胰岛的分离、处理和输注。 与公共健康相关：该项目旨在进行研究，以开发一系列被称为CellGuard的产品，该产品将在操纵过程中保护人类细胞。各种类型的人类细胞现在正被用于治疗癌症和糖尿病，也被用作生物医学领域中工程组织的构建块。操纵人类细胞以使其能够用于这些目的往往会损害细胞功能和生存能力。CellGuard产品组合旨在当这些细胞在临床应用的道路上受到这些恶劣条件的影响时保护它们。这个特别的项目旨在开发一种CellGuard补充剂，该补充剂将改进人类胰岛的分离和细胞治疗应用，从而改进治疗糖尿病的方法。

DESCRIPTION (provided by applicant): Tissue digestion and cell extraction is a core element of a variety of bioprocessing methods ranging from isolation of the rare cancer stem cell for basic research to the purification of human islets or adipose-derived mesenchymal stem cells for transplant. While procedures vary, it is clear that each tissue digestion procedure subjects the intact tissue to cell stress that can result in a loss of cell viability and function. CPSI-Bioech is focused on improving the bioprocessing of a variety of human cell types at normothermic temperatures (20 to 370C) so that their pharmacological and cell therapy utility can be improved. To this end the Company is developing the CellGuard supplement series - reagents that when added to select bioprocessing procedures will protect and maintain cell viability and function. This, in turn, will lead to fewer post-graft or transfusion problems in the patient. This Phase 1 project proposes to develop CellGuard-TD - a supplement designed to enhance tissue digestion (TD) of human pancreatic tissue for islet isolation (CTDislet). Phase 1 will use a variety of molecular biology methods to develop a prototype CTDislet- the first supplement designed to improve pancreatic islets digestion through cell stress pathway modulation. CTDislet will be based on the well documented apoptosis-prone nature of human pancreatic islets, their low cell yield as a result of warm ischemia exposure, and the collagenase-induced damage to islets that results in a low number obtained from each pancreas. Phase 2 studies will be dedicated to a more in depth analysis and development of CTDislet as well as testing this new formulation at select islets procurement centers. A second aim of the Phase 2 studies will be the development of a "non-synthetic" CTDislet formulation comprised of cell stress inhibitors derived from botanical sources. The intent of this project is to develop a supplement that protects the fragile nature of human pancreatic islets during the isolation and handling process- a technology that will apply to native islets as well as islets differentiated from mesenchymal stem cells and other stem cell sources. The human health consequence of this research will be to improve the isolation, handling and transfusion of human islets used for treating diabetes. PUBLIC HEALTH RELEVANCE: This project is designed to conduct research that will lead to the development of a series of products, termed CellGuard that will protect human cells during manipulation. A variety of human cell types are now being used to treat cancer, diabetes, and also serve as the building blocks of engineered tissues used in the biomedical field. Manipulating human cells such that they can be used for these purposes often compromises both cell function and viability. The CellGuard portfolio of products is designed to protect these cells when they are subjected to these harsh conditions on the path for clinical application. This particular project is designed to develop a CellGuard supplement that will improve the isolation and cell therapy application of human pancreatic islets leading to improved methods for treating diabetes.